Special Issue

Optimizing Antibiotics Therapy for Combating Difficult-to-Treat Infections by Multidrug-Resistant Gram-Negative Bacteria

Message from the Guest Editor

Infections due to multidrug-resistant Gram-negative bacteria represent a formidable hurdle in the treatment landscape and are a leading cause of illness and mortality, especially among critically ill patients. Gram-negative bacteria are responsible for many infections, including urinary tract, pneumonia, bloodstream, and intra-abdominal infections. In recent years, the adaptability of the Gram-negative bacteria and the emerging multidrug resistance have been one of the most urgent threats in the healthcare system and a challenge for clinicians. These challenges impact the ability to successfully treat bacterial infections and contribute to the global issue of antibiotic resistance. In response to this urgent need, we announce this Special Issue, inviting contributions from researchers at the forefront of microbiology, pharmacology, and clinical medicine. This Special Issue aims to assemble cutting-edge research that optimizes antibiotic strategies to effectively combat infections caused by these challenging pathogens.

Guest Editor

Dr. Paolo Gaibani

IRCCS Azienda Ospedaliera, Universitaria di Bologna, Policlinico di S.Orsola, Bologna, Italy

Deadline for manuscript submissions

closed (30 June 2024)

Antibiotics

an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed

mdpi.com/si/190923

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

mdpi.com/journal/antibiotics

Antibiotics

an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed

mdpi.com/journal/antibiotics

About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

MDPI